skip to content
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Last week, Resverlogix received a positive confirmation from the FDA that it would likely support approval of BETon MACE based on the result of its Phase 3 study. The stock moved up ~28% today. It shows great promise in treating types of cardiovascular disease. From your experience, is it normal for the FDA to offer a positive comment? Would you have an opinion based on the FDA comment to open a position? I am a prudent investor yet have room for higher risk opportunities.
Thank you
Read Answer Asked by Martin on June 19, 2018
Insiders
Share Information
News and Media